Learn more about the exciting field of intratumoral immunotherapy and OncoSec’s role as a key leader in this emerging space.
Watch the Video
OncoSec to Present Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2017
OncoSec Medical’s Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor Models
OncoSec Announces Second Quarter and YTD Results for Fiscal Year 2017
OncoSec Announces First Technology Access Program Agreement with Inhibrx
Our core technology platform continues to advance through clinical trials for various cancers.
The ImmunoPulse® platform is designed to boost the immune system to recognize and attack tumors.
OncoSec continues to establish relationships with industry leaders to further advance our research.
PDF | 2.0 MB
PDF | 1.0 MB